FDA approves Nexviazyme for late-onset Pompe disease
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
The transaction is expected to close in the Q4FY22
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
India produces 60% of the world’s vaccine
Subscribe To Our Newsletter & Stay Updated